The Supreme Court of India has directed the Union government to set up an expert committee to examine whether pharmaceutical companies should be brought under a legally enforceable framework to curb unethical marketing practices.
The petition before the Court raised concerns that pharma firms were allegedly offering doctors expensive gifts, overseas trips, and other incentives to encourage prescriptions of specific drugs. Such practices, critics argue, compromise medical ethics and patient welfare.
A Bench comprising Justices Vikram Nath and Sandeep Mehta instructed the Centre to constitute the panel in line with earlier judicial observations. The Court emphasized that unchecked promotional tactics could distort healthcare priorities, making regulation essential to safeguard public interest.
The move is seen as a significant step toward addressing long‑standing concerns about the nexus between pharmaceutical companies and medical professionals. Legal experts note that a binding framework could reshape industry standards, ensuring transparency and accountability in drug promotion.
For patients and advocacy groups, the order offers hope that medical decisions will be guided by genuine need rather than corporate incentives. The Centre’s forthcoming committee is expected to recommend measures balancing industry growth with ethical responsibility.
0 comments
No comments yet. Yours would be the first.